Atazanavir/r exposure is associated with an increased rate of renal stones compared with efavirenz, lopinavir/r and darunavir/r

Authors: Rockwood N, Mandalia S, Bower M, Gazzard B, Nelson M

There have been no data presented on the relative rates of the development of renal stones (RS) in those receiving ritonavir boosted atazanavir (ATZ/r) when compared with other commonly used antiretrovirals (ARVs).

We compared the rate of development of RS in a cohort of HIV infected individuals attending the Chelsea and Westminster Hospital Foundation Trust exposed to ATZ/r with those exposed to efavirenz (EFV)/lopinavir/r (LPV/r) and darunavir/r (DRV/r) over a 45 month study period.

The rate of development of RS in the ATZ/r group(n?=?1206) compared to the EFV/LPV/r/DRV/r combined group (n?=?4449) was 7.3 [95%CI: 4.7-10.8] per 1000 patient years and 1.9 [95%CI: 1.2-2.8] per 1000 patient years (p?

When choosing a boosted protease inhibitor, ATZ/r RS should be considered as a potential co-morbidity.

Copyright © 2011 MedicineJournalFeeds